News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

ImmunityBio, Inc. (NASDAQ: IBRX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $30.00 price target on the stock.

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock [Yahoo! Finance]

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

11/12/2024

07:15 am

IBRX

-12.5%

BEAT

5/9/2024

05:00 pm

IBRX

0.2%

MISS

Form 4 ImmunityBio, Inc. For: Dec 15 Filed by: LAUER REGAN J

Form 4 ImmunityBio, Inc. For: Dec 10 Filed by: SOON-SHIONG PATRICK

Form 424B5 ImmunityBio, Inc.

Form 8-K ImmunityBio, Inc. For: Dec 10

Form 8-K ImmunityBio, Inc. For: Dec 10

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}